Fig. 5
HuB6 induces antitumor immune memory and enhanced efficacy when combined with anti-PD-L1 mAb. a Changes of tumor volume after the treatment with HuB6 (MC38 model: 0.3 mg/kg, n = 5; Colo205 model: 10 mg/kg, n = 8) combined with atezolizumab (MC38 model: 0.5 mg/kg; Colo205 model: 10 mg/kg). b Relative tumor weight determined by comparison with the isotype control. Tumor tissues were removed and weighed at the end of the experiment in (a). c Schematic of the experimental design for testing antitumor immune memory. d Tumor volume changes in humanized 4-1BB mice subcutaneously inoculated with 2 × 106 MC38 cells and then intraperitoneally injected with 10 mg/kg HuB6 or utomilumab only once eight days later; the mice were given a secondary subcutaneous injection of 4 × 106 MC38 cells on day 45 (n = 6). Statistical analysis was performed using two-way ANOVA; *p < 0.05 compared to the isotype group, **p < 0.05 compared to the single antibody group. Error bars within the figure represent the mean ± SD